Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24 Month Open-label, Multicenter, Phase IIIb Study of the Efficacy and Safety of Lucentis (Ranibizumab 0.5mg) in Diabetic Patients With Visual Impairment Due to Macular Oedema Evaluating a Spaced Out Follow-up After Intensive Loading Phase

Next Previous
Trial Profile

A 24 Month Open-label, Multicenter, Phase IIIb Study of the Efficacy and Safety of Lucentis (Ranibizumab 0.5mg) in Diabetic Patients With Visual Impairment Due to Macular Oedema Evaluating a Spaced Out Follow-up After Intensive Loading Phase

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms CONSTELLATION
  • Sponsors Novartis Pharmaceuticals Corporation

Most Recent Events

  • 10 Jun 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov. Reason the study was stopped:Study was prematurely discontinued as it was unethical to continue based on a change inranibizumab (RFB) marketing authorization.
  • 09 Dec 2014 Planned End Date changed from 1 Feb 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
  • 09 Dec 2014 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top